Research programme: retinoid-related orphan receptor antagonists - Bristol-Myers Squibb/Exelixis

Drug Profile

Research programme: retinoid-related orphan receptor antagonists - Bristol-Myers Squibb/Exelixis

Alternative Names: RORγ antagonists - Bristol-Myers Squibb/Exelixis; RORγ-t antagonists - Bristol-Myers Squibb/Exelixis

Latest Information Update: 09 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; Exelixis
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 13 Oct 2010 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top